During the forecast period 2023 to 2033, the Nipah virus (NiV) infection testing market is expected to grow at a value of 5.2% CAGR, according to Future Market Insights. The market for Nipah virus (NiV) infection testing is anticipated to reach a market size of US$ 1,974.17 million in 2023 and US$ 3,277.49 million by 2033, exhibiting a CAGR of 5.2% during that time. The requirement for early detection and control of Nipah virus infection outbreaks can be linked to the growth of the market for Nipah virus (NiV) infection testing. In the historical period from 2018 to 2022, the market for Nipah virus (NiV) infection testing saw a CAGR of 3.1%.
The NiV infection testing market has become an important part of public health monitoring and disease surveillance for governments, healthcare providers, and the medical community. The NiV infection testing market has seen several advancements over the years. The latest developments include improved nucleic acid-based tests that offer higher accuracy and faster results. This has helped reduce the risk of false positives and enabled healthcare providers to identify infected individuals more quickly.
Request Sample @
https://www.futuremarketinsights.com/reports/sample/rep-gb-16756
In addition, the development of point-of-care testing devices for NiV infections has enabled healthcare providers to diagnose patients in remote areas without access to laboratory facilities. This has helped in the early detection and treatment of infected individuals in areas with limited healthcare resources. Furthermore, Asia Pacific along with Middle East and Africa are the largest contributors to the Nipah virus (NiV) infection testing market.
Key Takeaways from the Market Study
- The Nipah virus (NiV) infection testing market is expected to grow at a value of 5.2% CAGR in the forecast period 2023 to 2033
- By end user, hospitals are expected to possess 40% market share for Nipah virus (NiV) infection testing market in 2023.
- Asia Pacific is expected to possess 45% market share for Nipah virus (NiV) infection testing market in 2023.
- Middle East and Africa is expected to possess 39% market share for Nipah virus (NiV) infection testing market in 2023.
“The NiV infection testing market provides several benefits to the medical community and the general public. It enables healthcare providers to identify and treat infected individuals quickly and accurately. This helps reduce the spread of the virus and possible complications of the infection.” states an FMI analyst
Ask An Analyst @
https://www.futuremarketinsights.com/ask-question/rep-gb-16756
Competitive Landscape
Key players in the Nipah virus (NiV) infection testing market are Aurobindo, Minapharm, Roche, Lupin Ltd, Siegfried, Vivacure, Starlake Bioscience, Xaretto, Liferiver, MyBioSource, Krishgen Biosystems
- Aurobindo has developed a rapid diagnostic test for NiV, allowing clinicians to quickly detect the presence of the virus. Additionally, Aurobindo has used its expertise in the field of immunoassay and ELISA development to create an antibody test for NiV.
- In July 2020, Roche launched the cobas® NiV/HEV Assay. This test is a qualitative in-vitro diagnostic assay that detects NiV and HEV nucleic acid from human specimens and provides results in just under two hours.
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the global Nipah virus (NiV) infection testing market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
The study reveals essential insights on the basis of Types (Full Trisomy 18, Mosaic Trisomy 18, Partial Trisomy 18), Treatment (Cardiac Treatment, Assisted Feeding, Orthopaedic Treatment, Psychosocial Support, Others), End User (Hospitals, Clinics, Ambulatory Surgical Centres, Others), regions (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa).
Request Discount @
https://www.futuremarketinsights.com/request-discount/rep-gb-16756
Key Segments Profiled in the Nipah Virus (NiV) Infection Testing Industry Survey
Test Type:
- RT PCR based kits
- ELISA Kits
End User:
- Hospitals
- Research Labs
- Diagnostic Centres
About Us
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs